Effects of the Magenstrasse and Mill operation for obesity on plasma plasminogen activator inhibitor type 1, tissue plasminogen activator, fibrinogen and insulin

Pathophysiology of Haemostasis and Thrombosis

Volumn 32, Issue 1, 2002, Pages 40-43

  Carmichael, A R ^a,b   Tate, G ^a   King, R F G J ^a   Sue Ling, H M ^a   Johnston, D ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Fibrinogen; Fibrinolysis; Insulin; Obesity

Indexed keywords

FIBRINOGEN; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GASTROPLASTY; HUMAN; MAGENSTRASSE AND MILL OPERATION; MALE; MORBIDITY; MORTALITY; OBESITY; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY DISEASE; FEMALE; FIBRINOGEN; FIBRINOLYSIS; GASTROPLASTY; HUMANS; INSULIN; MALE; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0344980618     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057287     Document Type: Article

References (26)

1. Juhan-Vague I, Vague P: Hypofibrinolysis and insulin-resistance. Diabete Metab 1991;17:96-100.
2. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. 1988. Diabetes 1997;37:1595-1607.
3. Niewiarowski S, Rao AK: Contribution of thrombogenic factors to the pathogenesis of atherosclerosis. Prog Cardiovasc Dis 1983;26:197-222.
4. Schwartz CJ, Valente AJ, Kelley JL, Sprague EA, Edwards EH: Thrombosis and the development of atherosclerosis: Rokitansky revisited. Semin Thromb Hemost 1988;14:189-195.
5. Andersen T, Astrup A, Quaade F: Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: A randomized clinical trial. Int J Obes Relat Metab Disord 1992;16:35-40.
6. Kockx M, Leenen R, Seidell J, Princen HM, Kooistra T: Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss. Thromb Haemost 1999;82:1490-1496.
7. Ernst E, Weihmayr T, Matrai A, Resch KL: Changes in blood rheology of grossly obese individuals during a very low calorie diet. Int J Obes 1989;13(suppl 2):167-168.
8. Primrose JN, Davies JA, Prentice CR, Hughes R, Johnston D: Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost 1992;68:396-399.
9. Sylvan A, Rutegard JN, Janunger KG, Sjolund B, Nilsson TK: Normal plasminogen activator inhibitor levels at long-term follow-up after jejuno-ileal bypass surgery in morbidly obese individuals. Metabolism 1992;41:1370-1372.
10. Sugerman HJ, Kellum JM Jr, DeMaria EJ, Reines HD: Conversion of failed or complicated vertical banded gastroplasty to gastric bypass in morbid obesity. Am J Surg 1996;171: 263-269.
11. MacLean LD, Rhode BM, Forse RA, Nohr R: Surgery for obesity - an update of a randomized trial. Obes Surg 1995;5:145-150.
12. Rhode BM, Tamin H, Gilfix BM, Sampalis JS, Nohr C, MacLean LD: Treatment of vitamin B12 deficiency after gastric surgery for severe obesity. Obes Surg 1995;5:154-158.
13. Halverson JD: Micronutrient deficiencies after gastric bypass for morbid obesity. Am Surg 1986;52:594-598.
14. Abarbanel JM, Berginer VM, Osimani A, Solomon H, Charuzi I: Neurologic complications after gastric restriction surgery for morbid obesity. Neurology 1987;37:196-200.
15. Scopinaro N, Gianetta E, Adami GF, Friedman D, Traverso E, Marinari GM, Cuneo S, Vitale B, Ballari F, Colombini M, Baschieri G, Bachi V: Biliopancreatic diversion for obesity at eighteen years. Surgery 1996;119:261-268.
16. Kral JG: Overview of surgical techniques for treating obesity. Am J Clin Nutr 1992;55(suppl 2):552S-555S.
17. Summers G, Hocking MP: Surgical approach to the obese patient. J Fla Med Assoc 1992;79:396-399.
18. Johnston D, Sue-Ling HM: Surgical treatment of morbid obesity; in Cushieri A, Moosa AR, Giles GR (eds): Essential Surgical Practice. London, Butterworth-Heinemann, 1995, pp 1036-1044.
19. Clauss A: Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237-240.
20. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-1168.
21. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D: Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986;35:250-253.
22. Sundell IB, Nilsson TK, Ranby M, Hallmans G, Hellsten G: Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: A cross-sectional study in Norsjo, Sweden. J Clin Epidemiol 1989;42:719-723.
23. Meade TW, North WR, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, Brozovie M: Haemostatic function and cardiovascular death: Early results of a prospective study. Lancet 1980;i:1050-1054.
24. Ernst E, Resch KL: Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 1993;118:956-963.
25. Fowkes FG, Lowe GD, Housley E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J: Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993;342:84-86.
26. Banerjee AK, Pearson J, Gilliland EL, Goss D, Lewis JD, Stirling Y, Meade TW: A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost 1992;68:261-263.